Session » Systemic Sclerosis & Related Disorders – Clinical Poster III (1836–1861)
- 8:30AM-10:30AM
-
Abstract Number: 1859
Bone Mineral Density in Patients Diagnosed with Giant Cell Arteritis Taking Glucocorticoids: A Case-control Study
- 8:30AM-10:30AM
-
Abstract Number: 1840
Can Dual-energy CT Lung Perfusion Detect Abnormalities at the Level of Lung Circulation in Systemic Sclerosis (SSc) ? Preliminary Experience in 101 Patients
- 8:30AM-10:30AM
-
Abstract Number: 1850
Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Two-Year Data from SENSCIS-ON
- 8:30AM-10:30AM
-
Abstract Number: 1854
Disease Characteristics and Social Determinants in African Americans with Systemic Sclerosis: A Single Center Experience
- 8:30AM-10:30AM
-
Abstract Number: 1851
Early Intervention with Immunomodulators Leads to Better Outcomes in Patients with Systemic Sclerosis
- 8:30AM-10:30AM
-
Abstract Number: 1846
Effect of Nintedanib in Patients with Systemic Sclerosis-associated Interstitial Lung Disease and Risk Factors for Rapid Decline in Forced Vital Capacity: Further Analyses of the SENSCIS Trial
- 8:30AM-10:30AM
-
Abstract Number: 1844
Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated ILD (SSc-ILD) and Differing Comorbidity Burden: Subgroup Analyses of the SENSCIS Trial
- 8:30AM-10:30AM
-
Abstract Number: 1861
Epidermal Growth Factor Receptor Pathway and Fibrosis in Systemic Sclerosis Skin
- 8:30AM-10:30AM
-
Abstract Number: 1849
False Positive Anti-Topoisomerase I (Scl-70) Antibody Results: A Case Series from a Scleroderma Referral Center
- 8:30AM-10:30AM
-
Abstract Number: 1838
Further Construct Validation of the
- 8:30AM-10:30AM
-
Abstract Number: 1852
Healthcare Utilization and Economic Burden in Systemic Sclerosis
- 8:30AM-10:30AM
-
Abstract Number: 1839
Hispanic Patients with Systemic Sclerosis Have More Severe Disease and Higher Mortality: A Longitudinal Cohort Study
- 8:30AM-10:30AM
-
Abstract Number: 1837
KL-6, CXCL11 and CTGF Are Potential Biomarkers in Response to Treatment in CTD-ILD
- 8:30AM-10:30AM
-
Abstract Number: 1836
Outcomes Linked to Eligibility for Stem Cell Transplantation Trials in Diffuse Cutaneous Systemic Sclerosis
- 8:30AM-10:30AM
-
Abstract Number: 1843
Perceptions and Concerns Regarding COVID-19 Vaccination in Patients with Systemic Sclerosis in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort
- 8:30AM-10:30AM
-
Abstract Number: 1842
Peripheral Blood Cell Gene Expression Profiling Predicts Response to Mycophenolate in Systemic Sclerosis Related Interstitial Lung Disease
- 8:30AM-10:30AM
-
Abstract Number: 1841
Presence of Autoantibodies to Dense-Fine-Speckled 70 (DFS70) Do Not Necessarily Rule out Connective Tissue Diseases
- 8:30AM-10:30AM
-
Abstract Number: 1853
Scleroderma Presentation in the Canadian Scleroderma Research Group Indigenous Population
- 8:30AM-10:30AM
-
Abstract Number: 1856
Serum IFN Score Predicts Long Term Outcome in Limited Cutaneous SSc
- 8:30AM-10:30AM
-
Abstract Number: 1858
Serum Interferon Score Is a Biomarker of Active Disease in Patients with Early Diffuse Cutaneous Systemic Sclerosis Enrolled in the Prospective Registry of Early Systemic Sclerosis (PRESS) Cohort
- 8:30AM-10:30AM
-
Abstract Number: 1847
Severity of Gastroesophageal Reflux, but Not the Use of Proton Pump Inhibitors, Is Associated with Radiographic Progression of Interstitial Lung Disease in Systemic Sclerosis
- 8:30AM-10:30AM
-
Abstract Number: 1845
Six-minute Walk Test as a Prognostic Marker in Systemic Sclerosis
- 8:30AM-10:30AM
-
Abstract Number: 1860
Three Distinct Transcriptional Profiles of Monocytes Correlate with Disease Activity in SSc Patients
- 8:30AM-10:30AM
-
Abstract Number: 1857
Ultra-High Frequency Ultrasound Compared to Durometry and Skin Score for Cutaneous Assessment in Systemic Sclerosis
- 8:30AM-10:30AM
-
Abstract Number: 1848
Untangling the Gut: A Phenome-Wide Association Study of Drugs and Diseases with Gastrointestinal Dysfunction in Systemic Sclerosis